New pill targets Hard-to-Treat cancers in early trial

NCT ID NCT06305247

Ongoing Disease control Sponsor: Ipsen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 4 times

Summary

This study tests a new oral drug called IPN01194 in 36 adults with advanced solid tumours (melanoma, colorectal, pancreatic, or head and neck cancer) that have not responded to standard treatments. The goal is to find the right dose and check if it is safe, while also looking for signs that it can shrink tumours. All participants take the drug by mouth in 28-day cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IPN01194 (an ERK1/2 inhibitor taken orally)
What this could lead to: If successful, this could point toward a new treatment option for certain advanced solid tumours that have not responded to other therapies.
What could go wrong: This is an early, small trial (36 participants) focused on safety and dosing. The drug may not shrink tumours or could cause side effects. It is too soon to know if it will work.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm head and neck squamous cell carcinoma melanoma neoplasm pancreatic ductal adenocarcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER HEAD AND NECK SQUAMOUS CELL CARCINOMA MELANOMA PANCREATIC DUCTAL ADENOCARCINOMA SOLID TUMOR

Contacts and locations

Locations

Barcelona - Val D'Hebron

Barcelona, Spain
Centre Léon Bérard - Lyon

Lyon, France
Fundacion Jimenez Diaz - Madrid

Madrid, Spain
IGR-Villejuif

Villejuif, France
Institut de Cancerologie de l'Ouest (St-Herblain)

Saint-Herblain, France
M.D. Anderson Cancer Center Madrid

Madrid, Spain
Paris Saint-Louis

Paris, France
Sarah Cannon Research Institute (SCRI) - Nashville

Nashville, Tennessee, 37203, United States
The Angeles Clinic and Research Institute - California

Los Angeles, California, 90025, United States
Virginia Cancer Specialist

Fairfax, Virginia, 22031, United States
Yale Cancer Center - New Heaven

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.